The Pig-a assay, a recently developed in vivo somatic gene mutation assay, is based on the identification of mutant erythrocytes that have an altered repertoire of glycosylphosphatidylinositol (GPI)-anchored cell surface markers. We hypothesized that the erythrocyte Pig-a assay concept could be applied to rat cauda epididymal spermatozoa (sperm) for germ cell mutagenicity evaluation. We used GPI-anchored CD59 as the Pig-a mutation marker and examined the frequency of CD59-negative sperm using flow cytometry. A reconstruction experiment that spiked un-labeled sperm (mutant-mimic) into labeled sperm at specific ratios yielded good agreement between the detected and expected frequencies of mutant-mimic sperm, demonstrating the analytical ability for CD59-negative sperm detection. Furthermore, this methodology was assessed in F344/DuCrl rats administered N-ethyl-N-nitrosourea (ENU), a prototypical mutagen, or clofibrate, a lipid-lowering drug. Rats treated with 1, 10, or 20 mg/kg body weight/day (mkd) ENU via daily oral garage for five consecutive days showed a dosedependent increase in the frequency of CD59-negative sperm on study day 63 (i.e., 58 days after the last ENU dose). This ENU dosing regimen also increased the frequency of CD59-negative erythrocytes. In rats treated with 300 mkd clofibrate via daily oral garage for consecutive 28 days, no treatment-related changes were detected in the frequency of CD59-negative sperm on study day 85 (i.e., 57 days after the last dose) or in the frequency of CD59-negative erythrocytes on study day 29. In conclusion, these data suggest that the epidiymal sperm Pig-a assay in rats is a promising method for evaluating germ cell mutagenicity. Environ. Mol. Mutagen. 58:485-493, 2017. 
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INTRODUCTION
Regulatory agencies around the world have acknowledged the importance of germ cell mutagenicity assessment and have policies for managing germ cell mutagenic hazards. For example, the updated International Program on Chemical Safety (IPCS) harmonized scheme for mutagenicity testing states: "For substances that give positive results for mutagenic effects in somatic cells in vivo, their potential to affect germ cells should be considered. If there is toxicokinetic or toxicodynamic evidence that germ cells are actually exposed to the somatic mutagen or its bioactive metabolites, it is reasonable to assume that the substance may also pose a mutagenic hazard to germ cells and thus a risk to future generations" [Eastmond et al., 2009] . However, this assumption has not been rigorously tested using more recent methodologies. Based on the available data, the specificity of using short-term somatic cell mutagenicity tests to predict germ cell effects appears to be relatively low [Waters et al., 1994] . Unfortunately, the genetic toxicology field lacks practical, sensitive, animal-saving, and high throughput methods to detect genotoxic/mutagenic effects in the paternal and maternal germline [Singer and Yauk, 2010; Yauk et al., 2015] . Thus, there is an urgent need to develop appropriate germ cell mutagenicity tests that can be routinely conducted, ideally in an animal-saving and integrative testing manner.
The Pig-a assay is a recently developed test to evaluate the mutagenic potential of chemicals in somatic cells. It was developed from an understanding of the molecular nature of a rare human acquired genetic disorder, paroxysmal nocturnal hemoglobinuria (PNH) [Mortazavi et al., 2003] and was first introduced in 2008 to evaluate chemically induced mutagenicity in rodents Phonethepswath et al., 2008; Miura et al., 2008a,b] . Since then it has received extensive interest as a potential in vivo gene mutation assay for regulatory chemical safety assessment [Dobrovolsky et al., 2010; Schuler et al., 2011; Lynch et al., 2011b; Godin-Ethier et al., 2015; Gollapudi et al., 2015] . Multilaboratory trials initiated by Litron Laboratories [Dertinger and Heflich, 2011] , the Japanese Research Group [Kimoto et al., 2013] , and an ILSI-HESI initiative have contributed to evaluating the assay performance. The assay has been investigated extensively in peripheral blood erythrocytes of rats and has been performed with several types of hematopoietic cells and in a variety of mammalian species, including humans [Araten et al., 1999; Dobrovolsky et al., 2011; Dertinger et al., 2015] .
The Pig-a assay is based on the identification of mutant cells that have an altered repertoire of cell surface markers. The Pig-a gene (phosphatidylinositol glycan, class A gene) codes for the catalytic subunit of an N-acetyl glucosamine transferase that is required for glycosylphosphatidylinositol (GPI) biosynthesis. GPI anchors an assortment of proteins (e.g., CD59, CD24, and CD55) to the exterior surface of the cytoplasmic membrane. In mammals, Pig-a is an X-linked gene present as a single functional copy in cells from both males and females. Therefore, a single inactivating mutation in the Pig-a gene or its response element is sufficient to make a cell deficient in GPI biosynthesis and, as a consequence, deficient in surface-bound GPI-anchored proteins. As it is exceedingly unlikely that anchor deficiency would occur due to inactivating mutations in both copies of the autosomal genes involved in GPI synthesis, measuring GPI deficiency is considered 'virtually equivalent' to measuring Pig-a mutation [Mortazavi et al., 2003; Miura et al., 2008b; Kimoto et al., 2011; Miura et al., 2011] .
The purpose of this study was to assess whether the erythrocyte Pig-a assay concept could be applied to rat epididymal spermatozoa (sperm) for germ cell mutagenicity evaluation. In this manuscript, the method development of the rat sperm Pig-a assay and animal studies assessing the methodology using N-ethyl-N-nitrosourea (ENU), a prototypical mutagen, and clofibrate, a nongenotoxic lipid-lowering drug are presented. 
MATERIALS AND METHODS

Chemicals and Reagents
N
Animals
Male F344/DuCrl rats (Charles River Laboratories, Kingston, NY) were acclimated for at least one week prior to study start. Animals were housed two per cage in stainless steel cages under conditions of controlled temperature (20-268C), humidity (30-70%), light cycle (12 h, on at 6 am), and had access to food (LabDiet Certified Rodent Diet #5002, PMI Nutrition International, St. Louis, MO, USA) and municipal water ad libitum. Each animal was evaluated by a laboratory veterinarian, or a trained animal/toxicology technician under the direct supervision of a laboratory veterinarian, to determine the general health status and acceptability for study purposes. Before administration of test material, animals were stratified by body weight and then randomly assigned to treatment groups (5 animals per group) to minimize the difference in mean body weights between groups. Animals were approximately 7 weeks of age at the start of treatment.
The research facility, Toxicology and Environmental Research and Consulting (TERC), The Dow Chemical Company, Midland, Michigan, is accredited by the American Association for Accreditation of Laboratory Animal Care. All animal care and use activities were reviewed and approved by the Institutional Animal Care and Use Committee.
Sperm Pig-a Assay
Sperm Collection
Prior to sperm collection, 5 mL of Modified Sperm Washing Medium (IrvineScientific, Catalog No. 9984 , Santa Ana, CA) was aliquotted into 60 mm culture dishes and allowed to warm up in an incubator set at approximately 378C. Rats were anesthetized via inhalation of O 2 /isoflurane, and euthanized by cervical dislocation. The epididymides were dissected from the carcass, placed into a culture dish containing 5 mL of medium. The area where the epididymal corpus and cauda join was clamped with a hemostat and a hypodermic needle was used to puncture the caudal epididymis, releasing sperm into the medium. Sperm from both epididymides was collected immediately after puncture and pooled into one dish. After transferring the sperm sample into a 50 mL tube, the dish was rinsed with 5 mL of medium; therefore, sperm from each animal was collected into 10 mL medium. Sperm samples were stored at 2-88C for no more than 24 h prior to analysis.
Antibody Labeling and Nucleic Acid Staining
Prior to analysis, sperm quantity, and quality were assessed by light microscopy, which indicated a nearly pure, intact sperm population with no epithelial or epididymal cells. Sperm was washed with staining buffer [13 PBS buffer (Gibco, Catalog No. 14190-144) ] supplemented with 2% (v/v) heat inactivated fetal bovine serum (Gibco, Catalog No. 10082-139) by centrifugation (2000g, 10 min) and resuspended in staining buffer at a density of 40 3 10 6 /mL. Fifty microliters of this sperm suspension was transferred into 50 mL APC Mouse Anti-Rat CD59 (BD Bioscience, Catalog No. 562103) solution (80 mg/mL antibody in staining buffer). Sperm and antibody solution were gently mixed by pipette and then incubated in water bath at approximately 378C for 60 min, protected from light. Thus the final sperm density was 20 3 10 6 /mL and final antibody concentration was 40 mg/mL during labeling incubation. After incubation, 10 mL staining buffer was added to each sample and sperm was pelleted by centrifugation (2000g, 10 min). This rinse step Environmental and Molecular Mutagenesis. DOI 10.1002/em was repeated one more time to minimize the unspecific antibody bindings. Sperm was resuspended in 500 mL staining buffer and 1.5 mL of SYTO13 (Life Technologies, Catalog No. S7575) solution (133 nM in staining buffer) was added to the 500 mL sperm sample to achieve the final SYTO13 concentration of 100 nM. The sample was gently mixed by pipette and incubated at room temperature for 30 min, protected from light. After incubation, samples were analyzed on a flow cytometer.
Flow Cytometric Analysis
Samples were analyzed on a Gallios flow cytometer (Beckman Coulter) with Gallios Cytometer 1.2 software. The gating strategy to enumerate mutant and nonmutant sperm is illustrated in Figure 1 . In brief, sperm was captured based upon forward scatter and side scatter properties. Then single sperm was gated based upon the SYTO 13 fluorescent reading (excitation/emission 5 488/509 nm, PMT FL1, blue laser). The mutant (C59-negative) and nonmutant (C59-positive) sperm was defined by the APC fluorescent reading (excitation/emission 5 650/660 nm, PMT FL6, red laser). The fluorescence cutoff level for mutant sperm was set up by a sample only stained with SYTO 13 (not labeled with anti-CD59).
The flow rate was set at High during analysis and the speed was approximately 500 events/sec. Approximately 250,000 single sperm was captured for analysis per sample. Frequency of CD59-negative sperm (sperm CD59-) was calculated as Frequency of sperm CD59-5 "Mutant sperm"/"Single sperm" 3 10 26 .
Reconstruction Experiment
A rat sperm specimen was labeled with APC Mouse Anti-Rat CD59 and stained with SYTO 13 as described above. Sperm that was stained with SYTO 13, but not labeled with APC Mouse Anti-Rat CD59 were used to mimic the GPI-anchor deficient phenotype. The unlabeled (mutant-mimic) sperm was added into the labeled sperm at certain ratios and their frequencies were determined immediately after spiking. It was noted during method development that the mutant-mimic sperm population shifted towards the CD59-positive population with time after spiking, potentially as a result of the un-labeled sperm acquiring anti-CD59 antibody from the solution or the labeled sperm.
The ENU Study
ENU was prepared with an acidic buffer (pH 6.00, Ricca Chemical Company, Catalog No. 1510-32) and the concentration calculation was based upon the purity of 59% (40% water and 1% acetic acid as listed on Certificate of Analysis). The ENU dosing solutions were prepared on the day of administration. ENU was administered at the dose levels of 1, 10, or 20 mg/kg body weight/day (mkd) once daily for five consecutive days (study days 1-5) via oral gavage.
Five days prior to the first dose, blood was collected via tail vein to pre-screen the animals for erythrocyte Pig-a mutant frequency. On study day 63, animals were euthanized and blood was collected via the orbital sinus. Blood was collected into K 2 EDTA tubes (BD, Catalog No. 365973 ) and stored at 2-88C for no more than 24 h prior to analysis. The erythrocyte Pig-a assay was conducted using the MutaFlow PLUS Kit (Litron Laboratories, Rochester, NY, Catalog No. MutaFlow PLUS-25R), which utilizes a mutant enrichment step based on immunomagnetic column seperation to increase the sensitivity of this assay via evaluating a large number of cells, generally more than 3 3 10 6 reticulocytes (RETs) and 100 3 10 6 erythrocytes (RBCs) [Dertinger et al., 2011a] . Samples were analyzed on a Gallios flow cytometer (Beckman Coulter) with Gallios Cytometer 1.2 software, following the kit instructions.
On study day 63 (i.e., 58 days after the last dose on study day 5), animals were euthanized and mature sperm was collected from the caudal epididymis, as previously described. Sperm samples were stored at 2-88C for no more than 24 h and were analyzed as described above.
The Clofibrate Study
The clofibrate dosing solutions were prepared weekly with corn oil. Clofibrate was administered at the dose level of 300 mkd once daily for 28 consecutive days (study days 1-28) via oral gavage. Dosing volumes were adjusted daily based on individual body weights.
Blood was collected 5 days prior to the first dose and on study day 29 at necropsy for the pre-exposure and postexposure erythrocyte Pig-a analyses, respectively. The blood collection, storage, and erythrocyte Pig-a analysis procedures were the same as those used in the ENU study.
The sperm Pig-a assay was evaluated in three groups of animals, i.e., the untreated (no vehicle) control group, the vehicle (corn oil) control group, and the 300 mkd clofibrate group. After treatment with clofibrate via oral gavage for 28 consecutive days, the animals were kept for 56 additional days under conditions of controlled temperature (20-268C), humidity (30-70%), and light cycle (12 h, on at 6 A.M.) with access to food and municipal water ad libitum. Animals were euthanized on study day 85 (i.e., 57 days after the last dose on study day 28). Sperm was collected, stored, and analyzed as described above.
Statistical Analyses
All endpoints were tested for equality of variance using Bartlett's test at a 5 0.01. Based on the outcome of the Bartlett's test two variables in the ENU study (frequency of RET CD59-and frequency of RBC CD59-) were log-transformed. The dose effect was determined by a one-way analysis of variance (ANOVA) at a 5 0.05, which is equivalent to a ttest when there are only two dose groups in the analysis. In the ENU study, when the dose effect was significant, pairwise comparisons of treated vs. control group by Dunnett's t-test and linear dose-related trend tests were performed at a 5 0.05. Analyses were conducted in SAS/ STAT software, version 9.2 of the SAS System, Copyright 2002-2008, SAS Institute.
RESULTS
Reconstruction Experiment
The performance of the staining and data acquisition procedures was evaluated by a reconstruction experiment. The mutant-mimic sperm consisted of sperm that was lacking APC fluorescence (i.e., rat sperm that was stained with SYTO 13, but not labeled with APC Mouse Anti-rat CD59). The mutant-mimic sperm was added into labeled sperm at a series of ratios, i.e., 10/10 
The ENU Study
Five days prior to the initiation of exposure, tail vein blood was collected from all animals on study for prescreening the erythrocyte Pig-a mutant frequency. A high frequency (12.1 3 10 26 ) of CD59-negative reticulocyte (RET CD59-) exceeding the reported background range of 0-5 3 10 26 (Gollapudi et al., 2015) was identified in one animal, which was replaced with an animal with low frequency of RET CD59-(0.7 3 10 26 ) (data not shown). As shown in Table I , 5 days prior to the initiation of exposure, no appreciable differences in the frequencies of RET CD59-andCD59-negative erythrocyte (RBC CD59-) were observed between the animal groups. Postexposure blood samples were collected at necropsy on study day 63 (i.e., 58 days after the last dose on study day 5). As shown in Table I , significant increases in the frequency of RET CD59-or RBC CD59-were detected in the ENU-treated groups and the increase was dose-dependent (P < 0.05, trend test), demonstrating that the ENU treatment induced mutagenicity in somatic cells, even though a significant decrease in %RET was not observed at this time point. ENU-related reductions to %RET has been observed in blood samples collected at early time points, especially Environmental and Molecular Mutagenesis. DOI 10.1002/em between days 4 and 7, in other laboratories (Dertinger et al., 2011c) . At later time points, for example day 15, a rebound effect in %RET has been observed in rats treated with ENU for 3 days (days 1-3). After 1 month from the last dosing, generally no changes in %RET were present. All these observations indicate that erythropoiesis is well compensated after acute ENU treatment. Germ cell mutagenicity was evaluated in mature sperm collected from caudal epididymis on study day 63 (i.e., 58 days after the last dose on study day 5). The time point selection was based upon the approximately 50-day duration of normal spermatogenesis in rats (Adler, 1996) . The number of sperm collected from both epididymides per animal was estimated by counting via a hemocytometer. As shown in Table I , the sperm number per animal was dose-dependently decreased in ENU-treated groups, indicating that the 5-day ENU treatment induced severe cytotoxicity in spermatogenesis and the compensation was poor, comparing to that in erythropoiesis.
The average frequency of sperm CD59-was 88.4 3 10 26 in the vehicle control animals and was similar (82.6 3 10
26
) in the 1 mkd ENU group (Table I) . The average frequency of sperm CD59-in the 10 mkd ENU group was 146.6 3 10 26 , which was increased 1.7-fold relative to the control group, although the increase was not significant (P 5 0.0534). The average frequency of sperm in the 20 mkd ENU group was 231.5 3 10 26 , which was increased 2.6-fold relative to the control group and was statistically significant (P < 0.05). The increase in frequency of sperm CD59-was dose-dependent along with the ENU dose levels (P < 0.05, trend test).
The Clofibrate Study
Five days prior to the initiation of exposure, tail vein blood was collected from animals in the clofibrate group for prescreening the erythrocyte Pig-a mutant frequency. No animal was identified with a high frequency of RET CD59-exceeding the reported background range of 0-5 3 10 26 (Gollapudi et al., 2015) . Postexposure blood samples were collected on study day 29. As shown in Table II , no significant change in the frequency of RET CD59-or RBC CD59-was detected in the clofibrate treated group, suggesting that the clofibrate treatment (300 mkd 3 28 days) did not induce mutagenicity in somatic cells.
In comparison to the pre-exposure data, the postexposure %RET in both studies (study day 63 in the ENU study and study day 29 in the clofibrate study) was substantially decreased. This finding is consistent with the reports in rats from other labs, which indicate a biological aging phenomenon [Cammerer et al., 2011; Dertinger et al., 2011b,c; Lynch et al., 2011a; Stankowski et al., 2011; Dertinger et al., 2012; Kimoto et al., 2012; Torous et al., 2012; Dertinger et al., 2014; Gunther et al., 2014] .
Germ cell mutagenicity was also evaluated in sperm collected from caudal epididymis on study day 85 (i.e., 57 days after the last dose on day 28). As shown in Table  II , no significant differences in the number of sperm were observed between the untreated (no vehicle) control group, the vehicle (corn oil) control group, or the 300 mkd clofibrate group. The average frequencies of sperm CD59-were 65.1, 84.2, and 68.5 3 10 26 in the untreated control group, the vehicle control group, and the clofibrate group, respectively, and there was no statistically significant difference between these groups.
DISCUSSION
ENU is a prototypical mutagen [Kirkland et al., 2008] and its mode of action (MoA) and DNA targets have been well characterized. The product of ENU dissociation in aqueous solution, carbenium ion 1 C 2 H 5 , is electrophilic and reacts with electron-rich nucleophilic centers within DNA and proteins. It can alkylate both centers of high and low nucleophilicity and so is able to efficiently alkylate oxygen atoms (e.g., promutagenic O 6 -guanine site) [Beranek, 1990] . It is one of the recommended positive control substances for the transgenic rodent gene mutation assay in OECD Test Guideline 488. Furthermore, O'Brien et al., [2014] reported that ENU-induced gene mutations in germ cells were detected by the transgenic rodent mutation assay in cauda sperm. In that study, MutaMouse mice were administered with a single oral 
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Vehicle control 5 5.7 6 0.7 1.0 6 0.6 1.8 6 0.1 2.8 6 0.1 2.7 6 0.6 2.0 6 0.5 293 6 35 88.4 6 26.7 ENU 1 mkd 5 6.1 6 1.2 1.5 6 1.7 2.5 6 0.8 2.7 6 6 0.3 5.6 6 4.4 6.3 6 1.6 a 265 6 64 82.6 6 25.9 ENU 10 mkd 5 5.1 6 0.6 0.8 6 0.5 1.9 6 0.4 2.6 6 0. Environmental and Molecular Mutagenesis. DOI 10.1002/em dose of ENU and cauda sperm was collected 70 days after dosing. Acute ENU exposure induced a significant dose-dependent increase in the LacZ mutation frequency. The low (25 mg/kg), middle (50 mg/kg), and high dose (100 mg/kg) induced a 2.6-fold, 3.6-fold, and 4.4-fold increase, respectively over the controls, which had a baseline mutation frequency of 2.6 3 10
25
. In our current study, F344/DuCrl rats were treated with 1, 10, or 20 mkd ENU via daily oral gavage for five consecutive days; thus the accumulative doses were 5, 50, and 100 mg/kg, respectively. Cauda sperm was collected 58 days after the last dose and gene mutation was evaluated by the presence/absence of CD59 on spermatozoon surface. The low, middle, and high dose induced a 0.9-fold, 1.7-fold, and 2.6-fold increase, respectively over the controls, which had a baseline frequency of CD59-negative sperm of 8.8 3 10
. While the fold increases detected by the sperm Pig-a assay in rats were slightly lower than those observed with the transgenic rodent mutation assay in mice (albeit a slightly different dosing schedule) and the background frequency of CD59-negative sperm was slightly higher than the LacZ mutation frequency, the dose-dependent increase in frequency of CD59-negative sperm suggested the assay's capability to identify germ cell mutagens.
Clofibrate, a peroxisome proliferator activated receptora (PPAR-a) agonist, is a lipid-lowering drug used for controlling high levels of cholesterol and triacylglyceride in the blood. It is a member of a class of diverse exogenous and endogenous chemicals known as peroxisome proliferators. Though it has been shown that clofibrate produced hepatocellular carcinomas by oral administration in rats, the weight of evidence indicates that its MoAs of carcinogenicity in rats are induction of peroxisome proliferation and hepatocellular proliferation, but not mutagenic pathways [IARC, 1996; Corton et al., 2014] . In a transgenic rodent gene mutation study [Boerrigter, 2004] , male and female lacZ-plasmid based transgenic mice were treated at 4 months of age with six doses of 90 mg/kg over a 2-week period and liver tissue was collected 21 days after the last dose. The clofibrate treatment did not increase lacZ mutant frequency in liver of either male or female mice. Thus, we selected clofibrate, a nongenotoxic rodent carcinogen, as a "negative" compound to assess the sperm Pig-a assay. Clofibrate is readily absorbed and systemically distributed in blood after oral administration [Cayen et al., 1977] , and in the present study the increased liver weight (data not shown) demonstrated that clofibrate administration resulted in systemic and specific bone marrow exposure. As expected, no significant change in frequency of CD59-negative sperm was detected between the vehicle control animals and the ones treated with 300 mkd clofibrate via daily oral gavage for consecutive 28 days.
The reconstruction experiment and the preliminary animal studies with ENU and clofibrate demonstrated the assay's ability to differentiate germ cell mutagens and nonmutagens, but there are at least two critical biological questions to be answered in the assessment of this assay as an "in vivo germ cell gene mutation assay". First, similar to the erythrocyte Pig-a assay, is the phenotype (absence of GPI-anchored surface protein) equal to genotype (Pig-a gene mutation)? Sequencing the Pig-a gene in CD59-negative sperm will help to answer this question. Second, if the phenotype-genotype linkage is acceptable, is the mutant phenotype equal to gene mutation in germ cells? Even though the Pig-a gene is located at X chromosome and thus 50% of sperm lack the Pig-a gene, it is expected and also as observed in current study that GPI anchored proteins are present on all sperm regardless of the sex chromosome content presumably due to germ cell development in syncytia and sharing macromolecules (RNA and protein) across cytoplasmic bridges. Therefore the absence of CD59 on sperm may have resulted from a Pig-a gene mutation in stem germ cells; however, during post-testicular maturation of sperm, a variety of GPIanchored proteins, e.g., CD59, CD55, and CD52, are transferred from other cells of the seminiferous epithelium to the spermatozoon surface [Kirchhoff and Hale, 1996; Rooney et al., 1996; Kirchhoff et al., 1997] . Therefore, Pig-a gene mutation in the cells lining the lumen of the seminiferous tubule could theoretically also contribute to the absence of GPI-anchored proteins on spermatozoon surface. In other words, the detected CD59 absence on spermatozoon surface is possibly not only resulted from Pig-a gene mutation in germ cells, but also from non- There is another important question to be answered: is Pig-a gene mutation in sperm growth-neutral? Lines of evidence suggest that Pig-a gene mutation does not have significant impact on hematopoietic cell differentiation or proliferation [Peruzzi et al., 2010] . The observed persistence of CD59-negative erythrocytes over prolonged periods after chemical treatments [Miura et al., 2009; Phonethepswath et al., 2010] and additive effects of split doses of ENU [Miura et al., 2009] in the erythrocyte Piga assays support this growth-neutral property in erythropoietic cells. The potential impact of Pig-a gene mutation on spermatogenesis, however, is less defined.
In addition to the biological questions discussed above, there are also several technical concerns in this method. During method development, it was noticed that both the sperm density in the suspension for flow cytometric analysis and the flow rate (the sample volume running through the flow cytometer per second) produced substantial impact on CD59-negative sperm detection. As shown in Figure 3 , sperm density of the unlabeled (mutantmimic sperm) and labeled samples was adjusted to be 2 3 10 6 /mL. The unlabeled sperm was spiked into labeled sperm at a ratio of 1/10 3 . The lower sperm density samples were serially diluted from the 2 3 10 6 /mL sample with the DNA staining buffer. One flow cytometric analysis was performed for each density at each flow speed. Sperm density was negatively correlated with CD59-negative sperm detection in spiked nonexperimental samples (i.e., the sperm was collected from rats that were not treated with any chemicals). Meanwhile, lower flow rate yielded higher CD59-negative sperm detection. It is known that flow rate with increased event count per second increases the electronic abort rate that can result in sperm not being read for the presence of florescence. Another potential cause of these observations is the specific sperm morphology. At high sperm density or flow rate, it is possible that multiple sperm was flowing through the laser beam in tangle and were captured as one single spermatozoon. If this were the case, a CD59-negative spermatozoon flowing through with other CD59-positive sperm would be captured as CD59-positive. In preliminary experiments, the sperm tails were mechanically sheared before labeling with antibody (the tail pieces were visible under a microscope after shearing), as a means to preemptively avoid the potential tail tangling. However, a fluorescence signal "smear" of the CD59-positive population, extending to the CD59-negative population was generated, which was not acceptable because the "smear" substantially confounded the low background CD59-negative sperm frequency. Therefore, it was critical to process and analyze the sperm sample at the same density and keep flow rate the same across all samples during flow cytometric analysis. The results of the reconstruction experiment using spiked non-experimental samples (Fig.  2) indicated that the assay can still effectively detect CD59-negative sperm when the sperm density and flow rate were kept consistent across samples. Using a spermspecific antibody could be a further optimization approach facilitating appropriate gate of single sperm for CD59 presence determination.
In conclusion, our preliminary studies indicated that the sperm Pig-a assay in rats is a promising method to identify germ cell mutagens. Because of the obvious attractions, e.g., animal-saving by integration into repeated dose studies (e.g., 90-day toxicity studies) and relatively high-throughput analysis, future investigation is warranted to clarify the existing biological and technical questions. 
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